Translate Bio, Inc. [NASDAQ: TBIO] and Sanofi Pasteur, the vaccines global business unit of Sanofi have disclosed that they have decided to commence Phase I clinical trial assessing an mRNA-based investigational vaccine against seasonal influenza. It has been clarified by the firm that the trial will examine the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
In addition to this, Sanofi and Translate Bio have revealed that they have designed and will assess two formulations of the vaccine in the Phase I influenza mRNA vaccine clinical study. The two formulations of the vaccine include MRT5400 and MRT5401. The two creations differ in the lipid nanoparticle (LNP) that contains the mRNA.
The study follows a successful preclinical study that showed encouraging safety and immunogenicity. Preclinical results were shared earlier at the 8th annual mRNA Healthcare Conference in November 2020. The firm believed that the first clinical study of a seasonal mRNA flu vaccine candidate is an intriguing breakthrough in its search for the next generation of influenza vaccines.
Furthermore, the firm revealed that mRNA technology has provided encouraging results in the pandemic situation. Sanofi is always striving to focus on designing products that highlight protection ahead of the flu. This commitment of Sanofi is consistent with its global leadership and its 70-year of successful track record of safeguarding people with influenza vaccines.